(0)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company. These results are based on PatientView's annual survey of 207 U.S. patient groups who evaluated 38 pharmaceutical and biotechnology companies.
"Every day our patient advocacy team is working with patient groups to support their efforts toward improving the lives of people living with some of the most challenging diseases," said Matt Flesch, vice president, patient advocacy and communications, Horizon. "To be recognized by these patient groups who we have learned so much from and whose insights have guided nearly every facet of our work is an honor. We are humbled by the feedback provided within the PatientView report and look forward to continued opportunities to support the transformative work led by patient advocacy organizations around the world."